Additionally, the construction of a prognostic signature, anchored on genes linked to pro-tumor macrophages, distinguished high-score groups by elevated mutation frequencies in the TERT promoter region, reduced methylation of the MGMT promoter, adverse prognostic outcomes, and reduced efficacy of temozolomide therapy. The gene discussed is MGMT; the disease is neoplasm.